<DOC>
	<DOC>NCT01947959</DOC>
	<brief_summary>This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Phenprocoumon for the first time, the occurrence of intracranial haemorrhage, gastrointestinal and urogenital bleeding, and the occurrence of non-infective liver disease.</brief_summary>
	<brief_title>Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>All male and female patients who have been prescribed for the first time either Rivaroxaban or standard of care from the date of market authorization of rivaroxaban to Dec 31, 2017 Patients who have any record of being dispensed their index drug in the year before index date (i.e. cohort entry), or who qualify for both cohorts on the same day</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rivaroxaban</keyword>
	<keyword>Stroke Prevention in Atrial Fibrillation,</keyword>
	<keyword>Anticoagulants</keyword>
	<keyword>Hematologic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Observational</keyword>
	<keyword>Venous Thromboembolism</keyword>
	<keyword>Secondary Prevention of Acute Coronary Syndrome</keyword>
	<keyword>Intracranial Hemorrhages</keyword>
	<keyword>Gastrointestinal Hemorrhage,</keyword>
</DOC>